Abstract 104P
Background
A growing amount of data has indicated the possibility that tumor location may play a prognostic role in colon cancer. The present study set out to investigate the relation between the location of colon cancer (right side vs. left side) and the patient’s oncologic outcome.
Methods
This retrospective chart review studied 654 colon cancer patients who had been treated and followed up on at three tertiary hospitals between 2010 and 2015. To determine the most important independent factors of oncologic outcomes, the Cox regression multivariate analysis model used to analyze the prognostic impact of the primary tumor location and other clinical-, pathologic-, and treatment-related factors.
Results
In the univariate analysis, the prognostic factors for disease-free survival (DFS) were the primary tumor stage (< 0.001), node stage (<0.001), tumor grade (P = 0.013), surgical margin status (P = 0.001), lymphatic vascular invasion (LVI) (<0.001), and perineural invasion (PNI) (<0.001). Additionally, the prognostic factors for disease-free survival (OS) were the primary tumor stage (<0.001), node stage (<0.001), tumor grade (P = 0.036), presence of LVI (<0.001), presence of PNI (<0.001), and the mucinous type (P = 0.042). However, in the multivariate analysis, the presence of LVI, T3-4 lesions, tumor grade II-III, and an advanced disease stage remained independent prognostic factors for DFS as well as OS. However, the colon cancer location was not prognostic factor in terms of DFS or OS.
Conclusions
Although right-sided colon cancers present more aggressive clinical features, tumor location is not a significant prognostic factor for DFS and OS in colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The present study was approved by the University Research Ethics Committee and all procedures were performed in accordance with the ethical standards of the National Research Committee and with the Helsinki Declaration.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract